Skip to content

    Rainbow Child.

    RAINBOWGood
    Healthcare·26 May 2025
    Management Summary

    Rainbow Children's Medicare delivered a steady Q4 despite an unusually quiet season for pediatric volumes, which management described as a one-off. The company is entering a heavy expansion phase with 250 beds coming online in the next two quarters and a clear roadmap for Gurugram by 2027. Financial health remains a core strength, with high cash conversion and a debt-free balance sheet supporting all planned growth through internal accruals.

    Highlights

    7

    • Revenue for Q4 FY25 grew 8.5% YoY to ₹370.1 crores; full-year FY25 revenue reached ₹1,515.9 crores, up 16.9%.

    • EBITDA for the quarter stood at ₹114.7 crores with a margin of 31%; FY25 EBITDA was ₹489.9 crores (32.3% margin).

    • PAT for Q4 increased 10.7% YoY to ₹56.5 crores; full-year PAT grew 11.9% to ₹244 crores.

    • Overall occupancy rate for Q4 was 46.5%, with mature hospitals at 52.2% and new hospitals at 35.6%.

    • Cash position remains robust at ~₹700 crores as of March 31, 2025, supporting a ₹650 crore 3-year capex plan.

    • International revenue declined significantly to ₹30.7 crores in FY25 from ₹44 crores in the previous year due to visa challenges.

    • The company plans to add 250 beds in H1 FY26 across Rajahmundry (100) and Bengaluru (150).

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹370.1 Cr+8.5%YoY
    2. 02EBITDA Margin31%
    3. 03PAT₹56.5 Cr+10.7%YoY
    4. 04Occupancy Rate46.5%
    5. 05ARPP (Inpatient)5.6%+5.6%YoY

    Segment breakdown

    Pediatrics
    70% Revenue Share
    Mother Care (Maternity & Fertility)
    30% Revenue Share2.9% Fertility Revenue Share70% Fertility YoY Growth
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Margin
    Pre-Ind AS EBITDA Margin
    25%+
    		High
    Revenue
    Revenue CAGR
    18-20%
    		Medium
    Capex
    Total Capital Expenditure
    ₹650 crores
    		High
    Capacity
    New Bed Additions
    250 beds
    		High
    Capacity
    Gurugram Project Completion
    Oct-Nov 2027
    		Medium

    Risks & concerns

    4
    RiskSeverity

    International Business Decline

    Revenue dropped from ₹44cr to ₹30.7cr due to visa issuance challenges in key markets like Bangladesh and Sudan. — Management acknowledged

    medium

    Margin Pressure from New Beds

    Adding 250-280 beds typically creates a 0.5% to 1% drag on EBITDA margins in the short term. — Both acknowledged

    low

    Seasonality and Volume Volatility

    Q4 was unusually quiet for pediatrics (35% of business subdued), but management views this as a one-off deviation from long-term trends. — Management downplayed

    low

    Areas of Evasion(1)

    • Specific M&A targets (understandable due to confidentiality).

    Q&A highlights

    3

    “While full-year ARPOB was down 3.4%, the ARPP increase shows strong underlying revenue efficiency. So, ARPP is a more stable and relevant indicator, especially since ALOS is often outside our control.”

    Explains that the perceived decline in revenue per bed is actually due to longer patient stays (ALOS), while revenue per patient is actually increasing.

    asked by Damayanti Kerai, HSBC

    2 min read5 chapters

    Detailed Narrative

    01

    Operational Performance and Volume Trends

    Q4 FY25 was characterized by a 'modest' performance due to an unusually quiet season for pediatric care, which affected approximately 35% of the business including OPD visits and intensive care. Despite this, outpatient and inpatient volumes grew by 3% and 4% respectively for the quarter, while deliveries saw a 6% uptick. For the full year, the company maintained robust growth with outpatient volumes up 12% and inpatient volumes up 10%.

    02

    Aggressive Capacity Expansion Roadmap

    Rainbow is entering a significant growth phase, planning to add 250 beds in the first half of FY26. This includes a 100-bed regional hospital in Rajahmundry expected by the end of Q1 FY26 and two spoke hospitals in Bengaluru (Electronic City and Hennur) totaling 150 beds by the end of Q2 FY26. Project work has also commenced on a 130-bed regional hub in Coimbatore, with a 20-24 month completion timeline.

    03

    Financial Resilience and Margin Guidance

    The company reported a healthy EBITDA margin of 31% for Q4 and 32.3% for FY25. Management has set a conservative internal benchmark for a pre-Ind AS EBITDA margin of over 25%, even when accounting for the 0.5% to 1% margin pressure typically associated with new bed additions. Cash generation remains a highlight, with ₹481.2 crores generated from operations, representing a 90% conversion rate from EBITDA.

    04

    Strategic Shift: ARPOB vs. ARPP

    Management addressed concerns regarding a 3.4% decline in full-year ARPOB by highlighting a 7.7% rise in Average Length of Stay (ALOS). They urged investors to focus on Average Revenue Per Patient (ARPP), which grew by 5.6% YoY. This shift in metrics suggests that while beds are occupied longer, the underlying revenue efficiency per patient remains on an upward trajectory.

    05

    Growth Drivers: IVF and Tertiary Care

    The IVF business is emerging as a key growth driver, now operational in 12-13 hospitals and growing at nearly 70% YoY. It contributed 2.9% to Q4 revenue. Additionally, the company is strengthening its tertiary care capabilities, having performed its first pediatric liver transplant in Chennai and securing a transplant license for its Bengaluru hub.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.